We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Domain Therapeutics announced a collaboration agreement with Pfizer aimed at assessing the impact of mutations on different signaling pathways engaged by G protein-coupled receptors (GPCRs).